Estimation of Endothelin-1 and Vitamin D Levels in Patients with Some Renal disease

Ihsan Maher Abdul Amir, Moafaq Mutlak Zeidan
Biology Department, College of Sciences, Tikrit University, Tikrit, Iraq

Article history:
- Received: 29/5/2019
- Accepted: 6/8/2019
- Available online: / 2019

Keywords: Endothelin-1; Vitamin D, Chronic renal disease, Acute Renal Disease

Corresponding Author:
Name: Ihsan Maher Abdul Amir
E-mail: ahssanbaladbalad@gmail.com
Tel:

ABSTRACT

Chronic renal disease is a worldwide public health problem with an increasing incidence, prevalence, poor outcomes, and high cost. A cross-sectional study was carried out in Balad city from 10th of November 2018 to 15th of March 2019. The number of patients under study were 60 patients with renal disease (30 acute renal disease and 30 chronic renal disease under hemodialysis). Their ages were between (20-75) years. Patients with acute renal disease were admitted to Balad general hospital and patients with chronic renal disease who admitted to Salahaddin general hospital for hemodialysis. The study included 30 apparently healthy subject as control group. The results showed that the highest mean level of endothelin-1 was found in patients with chronic renal disease (13.15±7.81) pg/ml followed by patients with acute renal disease (1.78±1.49) pg/ml compared with the control group (0.41±0.31) pg/ml. These result were significant higher (P< 0.01). The results showed that the lowest mean level of vitamin D was found in patients with chronic renal disease (14.45±5.92) ng/ml followed by patients with acute renal disease (23.49±13.14) ng/ml compared with the control group (24.02 ±8.22) ng/ml. The results were significant higher than control (P<0.01). The study showed that patients with acute renal disease were distributed equally to male and female (1:1) while 56.67% of patients with chronic renal disease were males. The conclude from this study that the endothelin elevated in chronic renal disease patients and vitamin D was reduced.

Introduction

Unlimited renal disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic renal disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease[1]. Current evidence suggests that some of these adverse outcomes can be prevented or delayed by early detection and treatment [2,3]. The major outcomes of chronic renal disease, regardless of cause, include progression to kidney failure, complications of decreased kidney function, and cardiovascular disease (CVD). Strikingly the unlimited renal disease is undiagnosed and undertreated, resulting the opinion for uniform application of simple tests for detection and evaluation [1].

Over the last decade, a pivotal role for the Endothelin-1 system has been documented in normal renal function, as well as in renal disease. In the kidney, Endothelin-1 acts in an autocrine and paracrine manner in renal vessels and nephron segments, modulating renal hemodynamics and tubular water and sodium reabsorption, respectively [4]. Therefore, Endothelin-1 is a key factor contributing to the extracellular volume and blood pressure homeostasis. Alterations of the Endothelin-1 system have been documented in renal diseases in which cardiovascular illness including hypertension and endothelial dysfunction coexist [5]. Individuals obtain vitamin D either through consuming vitamin D-rich foods (oily fish, dairy products) or supplements, or through the skin’s exposure to ultraviolet B radiation producing vitamin D [6]. Under physiological conditions, 1,25(OH)2–VD is mainly metabolized in the kidneys but in abnormal conditions, such as pregnancy, chronic kidney failure,
rheumatoid arthritis and granulomatous diseases, other cell types can also contribute to its circulating levels. Moreover, there is an increasing body of evidence about the pivotal role of extra-renal 1α-
hydroxylation for autocrine and paracrine effect[7,8]. The study aimed at estimation of Endothelin-1 and vitamin D in sera of in patients with renal failure and normal healthy control.

Materials and Methods
A cross sectional study was carried out in balad city for the period between the 10th of November 2018 to 15th of March 2019. The number of patients under study were 60 patients with renal disease (30 acute renal disease and 30 chronic renal disease under hemodialysis). Their ages were between (20-75) years. Patients with acute renal disease were admitted to Balad general hospital and patients with chronic renal disease who admitted to Salahaddin general hospital for hemodialysis. The study included 30 apparently healthy subject as control group, whose age were between (15-70) years.

Methods
Five ml of blood sample was taken by vein puncture from each subject enrolled in this study. Blood samples were centrifuged, the serum were separated and kept for estimation of human endothelin-1 by ELISA and vitamin D by immunofluorescence assay.

Statistical analysis
Computerized statistically analysis was performed using Minitab ver. 18 statistic program. Comparison was carried out using T-Test for determination of probability (P) value. The P value < 0.05 was considered statistically significant and P value greater than 0.05 considered non-significant statistically.

Results
The results showed that the highest mean level of Endothelin-1 was found in patients with chronic renal disease (13.15±7.81) pg/ml followed by patients with acute renal disease (1.78±1.49) pg/ml compared with the control group (0.41±0.31) pg/ml. These results were significant higher than control (P< 0.01), as shown in Table 1.

The results showed that the lowest mean level of vitamin D was found in patients with chronic renal disease (14.45±5.92) ng/ml followed by patients with acute renal disease (23.49±13.14) ng/ml compared with as show in the control group (24.02 ±8.22) ng/ml. The result were significant higher than control (P<0.001), Table 1.

| Biochemical parameter | Healthy control Mean± SD NO=30 | Patients with renal disease | Chronic renal disease with control group P.val uc |
|-----------------------|---------------------------------|-----------------------------|-----------------------------------------------|
| Endothelin 1 Level (pg/ml) | 0.41±0.31 | 1.78±1.49 * | 13.15±7.81 * | 0.004 8 |
| Vitamin D Level (ng/ml) | 24.02±8.14 | 23.49±13.14 * | 14.45±5.92 * | 0.000 2 |

*Significant different between control at (p<0.001)

The study showed that patients with acute renal disease were distributed equally to male and female (1:1) while 56.67% of patients with chronic renal disease were males, as show in Figure 1.

Discussion
The result of the current study was in consistence with Larivière, et al [9] study, who showed that, plasma Endothelin-1 concentrations are markedly increased in patients with end-stage renal disease undergoing dialysis as compared with healthy individuals. Rebholz, et al [10] also found that Endothelin-1 was more likely to be elevated in hemodialysis patients. Shah, [11] indicated that Endothelin-1 was activated in several diseases, including renal failure and arterial hypertension. Additionally, El-Shafey, et al [12] found that level of Endothelin-1 was significantly higher in dialysis patients compared to the controls (P < 0.001). Dhaun, et al [13] demonstrated that Endothelin-1 level was significantly correlated with the progression of Chronic renal disease and the highest level was found in end stage hemodialysis patients and the minimum level was among healthy control. These increases in ET-1 in chronic renal disease patients are likely due in part to reduced renal clearance from the circulation and/or to increases in synthesis [14]. There is also strong evidence that the activation of the endothelin system directly promotes renal fibrosis, as rats with transgenic overexpression of endothelin-1 develop severe glomerulosclerosis and interstitial fibrosis [15]. Cell culture studies have further shown that exposure to protein overload, as a general model of proteinuric
nephropathies, and exposure to shigatoxin, as a model for the haemolytic uraemic syndrome, both upregulate Endothelin-1 expression in cultured podocytes [16]. The release of Endothelin-1 then results in further deterioration of podocyte structure and function by an autocrine mechanism [15]. In agreement with our findings, in Firth, et al [17] study, plasma levels of endothelin-1 and/or renal expression of endothelin-1 have been reported to be elevated in acute renal disease. Endothelin-1 may play a role in the development of acute renal failure, which most commonly arises due to renal vasoconstriction and subsequent ischaemic necrosis of renal tubules [18].

Over the years, studies have improved the understanding of the biological and clinical consequences of the interaction between disordered vitamin D metabolism and chronic renal disease. Vitamin D deficiency are now becoming a global epidemic problem in patients with chronic renal disease [19]. Several observational studies have demonstrated an important link between vitamin D deficiency, impaired glomerular filtration rate (GFR), and increased mortality in patients with chronic renal disease [20,21]. Moreover, Lundwall, et al [22] found that activated vitamin D treatment reduces all-cause and cardiovascular mortality rates in patients with chronic renal disease and those undergoing hemodialysis. The critical role of the vitamin D endocrine system in disease prevention extends beyond the classic regulation of calcium and phosphorous homeostasis and skeletal integrity, to its potentially pleiotropic effects on extra-mineral metabolism, including kidney function [6].

High prevalence of vitamin D deficiency or insufficiency in patients with Chronic renal disease has been well documented in recent epidemiological studies [23,24]. In a previous study, a serum 1,25(OH)₂D decline was observed during early stages of chronic renal disease, comparing with healthy control [25]. Interestingly, a retrospective study showed that serum 25(OH)D is an independent inverse predictor of renal disease patients with earlier stages of Chronic renal disease [26]. These clinical data suggest that the association between vitamin D and renal disease.

Patients with chronic renal disease, especially on hemodialysis, are likely to have less sunlight exposure [6]. Valle, et al [27] showed that 84% of the hemodialysis patients with vitamin D deficiency had inadequate sunlight exposure. Uremia may also decrease the response of plasma vitamin D to ultraviolet B irradiation [28]. Chronic hemodialysis patients exhibited a lower vitamin D response than normal individuals when exposed to a physiologically equivalent dose of ultraviolet B [29]. Nutritional factors may also contribute to suboptimal 25(OH)-vitamin D status in Chronic renal disease. Patients with Chronic renal disease frequently have low food intake due to numerous reasons such as reduced appetite, uremic-related gastrointestinal symptoms and dietary restrictions, i.e., low protein (especially in those on preservation is the board) and low phosphate diets [25,30].

Because differences in men’s and women's physiology have widely been recognized, researchers are encouraged to evaluate clinical study data by sex [7,8]. Important sex-specific distinctions have been recognized in several of the most prevalent medical conditions, such as obesity, type 2 diabetes mellitus, cardiovascular disease, and depression [31]. Many of these conditions coexist with, or may have contributed to, chronic renal disease [32]. Chronic renal disease in itself raises numerous gender questions, for example, regarding sex-dependent prevalence and disease awareness [33]. Sex-specific differences in the characteristics, treatment, and outcomes for individuals on renal replacement therapy have, however, only once previously been the primary theme in an international study, and with focus on mortality patterns at the start of dialysis [7,8].

**Conclusions**

It was concluded from our result that endothelin elevated in chronic renal disease patients and vitamin D was reduced.

**References**

[1] Brophy, P.D., Charlton, J.R., Carmody, J.B., Reidy, K.J., Harshman, L., Segar, J., Askenazi, D., Shoham, D. and Bagby, S.P., (2018). Chronic renal disease: A life course health development perspective. In: Handbook of Life Course Health Development. Springer, Cham: 375-401.

[2] Akchurin, M. and Kaskel, F., (2015). Update on inflammation in chronic renal disease. Blood purification, 39(1-3): 84-92.

[3] Edelstein, C.L. (2016). Biomarkers of renal disease. 1st edn. Academic press: 109 pp.

[4] Komers, R. and Plotkin, H., (2016). Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic renal disease. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 310(10): 877-884.

[5] Ramkumar, N., Stuart, D., Abraham, N. and Kohan, D.E., (2018). Nephron Prorenin Receptor Deficiency Alters Renal Medullary Endothelin-1 and Endothelin Receptor Expression. Physiological Research, 67(1): 127-136.

[6] Lu, R. J. et al. (2017). Effects of vitamin D or its analogues on the mortality of patients with chronic renal disease: an updated systematic review and meta-analysis. European Journal of Clinical Nutrition, 71(6): 683-687.

[7] Carrero, J. J., Hecking, M., Chesnaye, N. C. and Jager, K. J. (2018). Sex and gender disparities in the
epidemiology and outcomes of chronic renal disease. *Nature Reviews Nephrology*, 14(3): 151-156.

[8] Dogara, L. G. et al. (2018). Influence of Age and Gender on the prevalence of anaemia in dialysis naïve Patients with chronic renal disease (CKD) in Zaria, Nigeria. *Tropical Journal of Nephrology*, 13(2): 69-76.

[9] Lariviére, R. and Lebel, M. (2003). Endothelin-1 in chronic kidney failure and hypertension. *Canadian Journal of Physiology and Pharmacology*, 81(6): 607-621.

[10] Rebolz, C. M. et al. (2017). Association between endothelin-1 levels and renal disease among blacks. *Journal of the American Society of Nephrology*, 28(11): 3337-3344.

[11] Shah, R. (2007). Endothelins in health and disease. *European Journal of Internal Medicine*, 18(4): 272-282.

[12] El-Shafey, E. M., El-Nagar, G. F., Selim, M. F., El-Sorogy, H. A., and Sabry, A. A. (2008). Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis. *Clinical and Experimental Nephrology*, 12(5): 370-375.

[13] Dhaun, N. et al. (2015). Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Renal disease and Following Selective Endothelin A Receptor Antagonism. *Journal of the American Heart Association*, 4(3): e001624.

[14] Wang, C. et al. (2015). Thromboxane prostanoid receptors enhance contractions, endothelin-1, and oxidative stress in microvessels from mice with chronic renal disease. *Hypertension*, 65(5): 1055-1063.

[15] Lawson, J., Elliott, J., Wheeler-Jones, C., Syme, H. and Jepson, R. (2015). Renal fibrosis in feline chronic renal disease: known mediators and mechanisms of injury. *Veterinary Journal*, 203(1): 18-26.

[16] Zoja, C. et al. (2015). Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic renal disease. *Experimental Nephrology*, 129(1): 52-61.

[17] Firth, J. D., Raine, A. E. G., Ratcliffe, P. J. and Ledingham, J. G. G. (1988). Endothelin: an important factor in acute renal failure?. *The Lancet*, 332(8621): 1179-1182.

[18] Guan, Z., Van Beusecom, J. P. and Inscho, E. W. (2015). Endothelin and the renal microcirculation. *Seminars in Nephrology*, 35(2): 145-155.

[19] Yasin, T. and Siddiqui, M. S. I. (2018). Prevalence of Vitamin D & Renal Dysfunction in Metabolic Syndrome. *International Archives of BioMedical and Clinical Research*, 4(2): 179-183.

[20] Nakashima, A., Yokoyama, K., Yokoo, T., & Urashima, M. (2016). Role of vitamin D in diabetes mellitus and chronic renal disease. *World Journal of Diabetes*, 7(5): 89.

[21] Bhan, I. et al. (2015). Nutritional vitamin D supplementation in dialysis: a randomized trial. *Clinical Journal of the American Society of Nephrology*, 10(4): 611-619.

[22] Lundwall, K., Jacobson, S. H., Jörneskog, G. and Spaak, J. (2018). Treating endothelial dysfunction with vitamin D in chronic renal disease: a meta-analysis. *BMC Nephrology*, 19(1): 247-252.

[23] Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T. and Dawson-Hughes, B. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *The American Journal of Clinical Nutrition*, 84(1): 18-28.

[24] Nigwekar, S. U., Bhan, I. and Thadhani, R. (2012). Ergocalciferol and cholecalciferol in CKD. *American Journal of Renal diseases*, 60(1): 139-156.

[25] Levin, A. et al. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic renal disease: results of the study to evaluate early renal disease. *Kidney International*, 71(1): 31-38.

[26] Ravani, P. et al. (2009). Vitamin D levels and patient outcome in chronic renal disease. *Kidney International*, 75(1): 88-95.

[27] Valle, E. D., Negri, A. L., Aguirre, C., Fradinger, E. and Zanchetta, J. R. (2007). Prevalence of 25 (OH) vitamin D insufficiency and deficiency in chronic renal disease stage 5 patients on hemodialysis. *Hemodialysis International*, 11(3): 315-321.

[28] Kleine, C. E. et al. (2019). Seasonal variation of serum 25-hydroxyvitamin D and parameters of bone and mineral disorder in dialysis patients. *Bone*, 124: 158-165.

[29] Ahmadi, F. et al. (2016). Association of low vitamin D levels with metabolic syndrome in hemodialysis patients. *Hemodialysis International*, 20(2): 261-269.

[30] Mohiuddin, S. A., Marie, M., Ashraf, M., Hussein, M. and Almalki, N. (2016). Is there an association between Vitamin D level and inflammatory markers in hemodialysis patients? A cross-sectional study. *Saudi Journal of Renal diseases and Transplantation*, 27(3): 460-466.

[31] Brar, A. and Markell, M. (2019). Impact of gender and gender disparities in patients with renal disease. *Current Opinion in Nephrology and Hypertension*, 28(2): 178-182.

[32] Goldberg, I. and Krause, I. (2016). The role of gender in chronic renal disease. *European Medical Journal*, 1(2): 58-64.

[33] Ito, J., Kita, H. and Fujisawa, T. (2018). Significance of early detection of acute kidney function worsening among outpatients having CKD using automatic calculation system for the rate of eGFR decline. *Clinical and Experimental Nephrology*, 22(4): 898-905.
تقدير مستويات الإندوثيمين-1 و فيتامين-D في المرضى الذين يعانون من بعض أمراض الكلى

احسان ماهر عبد الأمير ، موفق مطاك زيدان
قسم علوم الحياة ، كلية العلوم ، جامعة تكريت ، تكريت ، العراق

الملخص

مرض الكلى المزمن هو مشكلة صحية عامة في جميع أنحاء العالم مع زيادة معدل الإصابة، والانتشار، ونتائج سلبية، وأرتفاع تكلفة. أجريت هذه الدراسة في مدينة تكريت في الفترة من 10 نوفمبر 2018 إلى 15 مارس 2019. وكان عدد المرضى في الدراسة 60 مريضا يعانون من مرض كلي مزمن (30 مريضا يعانون من مرض كلي حاد) و 30 مريضا يعانون من مرض كلي مزمن (20-75) سنة. تم إدخال المرضى الذين يعانون من مرض كلي حاد في مستشفى تكريت العام والمرضى الذين يعانون من مرض كلي مزمن الذين دخلوا مستشفى صلاح الدين العام لعملية الكلى في وحدة الكلية الصناعية. وشملت الدراسة أيضا 30 من الأشخاص الاصحاب كمجموعة سيطرة. أظهرت النتائج أن أعمى متوسط لمستوى الإندوثيمين (7.81 ±13.15) pg/ml عالية في المرضى الذين يعانون من مرض كلي حاد (1.49 ±1.78) pg/ml مقارنة مع مجموعه السيطرة (0.31 ±0.41) pg/ml. والنتائج أظهرت أن أعمى متوسط لمستوى فيتامين D (5.92 ±14.45) ng/ml في المرضى الذين يعانون من مرض كلي حاد (13.45 ±23.49) ng/ml مقارنة مع مجموعه السيطرة (8.22 ±24.02) ng/ml. وظاهرت هذه الدراسة أن المرضى الذين يعانون من مرض كلي حاد ذو المؤكسدات على الذكور والإناث (1:1) في حين أن 56.67% من المرضى الذين يعانون من مرض كلي مزمن كانوا من الذكور. نحتاج هذه الدراسة لتشير إلى ارتفاع مستويات الإندوثيمين-1 في مرضى الكلى المزمن والانخفاض في فيتامين D.